Abstract
* Denosumab has been approved under the trade name Xgeva for use in patients with metastasized cancer to help prevent bone-related events.
* Clinical trials found denosumab to be superior to zoledronic acid in delaying the onset of such events in patients with metastatic breast or prostate cancer.
* Serious adverse effects of denosumab include hypocalcemia and osteonecrosis of the jaw.